

What is the commercial opportunity for MYCAPSSA?

Based on available data, we estimate there are approximately 24,000 people diagnosed with acromegaly in the U.S. and 69,000 people in the developed world. For many patients, acromegaly is cured through the successful surgical removal of the pituitary tumor. However, for an estimated 10,000 people in the U.S., managing the disease remains a life-long challenge. Chiasma estimates that approximately 8,000 of these patients are on chronic somatostatin analog (SSA) injectables in the U.S., primarily octreotide and lanreotide. Additionally, Chiasma estimates approximately 90% of patients are managed by less than a 1,000 medical accounts. Chiasma believes the acromegaly market is an attractive commercial opportunity – based on the market shares and prices in 2019, the U.S. market was estimated to be half of the global market – at approximately \$400M.

Date: June 26, 2020